Breaking Stories

Needham gives Biogen a buy rating, predicts big rally despite controversy around Alzheimer’s drug

The rollout of Aduhelm is facing “near-term challenges,” according to Biogen.

What's your reaction?

Excited
0
Happy
0
In Love
0
Not Sure
0
Silly
0

You may also like

Leave a reply

Your email address will not be published. Required fields are marked *